公司資料
Pyxis Oncology 股價、新聞與催化劑
- 股票代碼:
- PYXS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
3.02 USD (+0.33%)
收盤價
最後更新: 2026年8月17日
108M USD
市值
股價為何變動
As of Aug 17, 2026, PYXS closed up 0.33% at $3.02. No new same-company headline was identified in the current news window.
公司概覽
Tumor-Microenvironment ADC Company
Pyxis Oncology develops antibody-drug conjugates for difficult-to-treat cancers, with a strategy that targets structural components of the tumor microenvironment.
MICVO
Micvotabart pelidotin, or MICVO, targets extradomain-B fibronectin, a non-cellular component enriched in tumor tissue. This approach is intended to deliver a cytotoxic payload across heterogeneous tumors without relying on uniform tumor-cell antigen expression.
Head and Neck Cancer Focus
MICVO is being evaluated as monotherapy in previously treated recurrent or metastatic head and neck squamous cell carcinoma and with pembrolizumab in the first-line setting.
未來催化劑
- Updated Phase 1 monotherapy data for MICVO in second-line or later head-and-neck cancer in fall 2026.
- Updated Phase 1/2 data for MICVO plus pembrolizumab in first-line head-and-neck cancer in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。